4 quarters tracked · Beat rate 25% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $7.01 | $5.82 | -16.9% | Miss |
| Q4 2025 | 2025-12-31 | $7.33 | $7.70 | +5.1% | Beat |
| Q3 2025 | 2025-09-30 | $7.33 | $7.16 | -2.3% | Miss |
| Q2 2025 | 2025-06-30 | $7.08 | $6.41 | -9.5% | Miss |
Earnings Beat Rate
United Therapeutics has beaten analyst EPS estimates in 1 of 4 tracked quarters (25% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →